1AI · ASX

Algorae Pharmaceuticals Limited (ASX:1AI)

AU$0.006

 0.0 (0.0%)
ASX:Live
16/05/2025 12:00:00 AM
HALO Ords GROWTH AUS Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

1AI Overview

1AI Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About 1AI

Website

Algorae Pharmaceuticals Limited

Telephone

61.4.2218.0317

Address

Level 23 Rialto South Tower 525 Collins Street Melbourne, Victoria (VIC) 3000

Description

Algorae Pharmaceuticals Ltd. operates as an artificial intelligence enabled drug discovery and development company. It engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company was founded by Robert Bartlett Elliot and David Collinson in 1987 and is headquartered in Mount Eden, New Zealand.

1AI Price Chart

Key Stats

Market Cap

AU$11.81M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$2,050.00

1 week

-14.29%

1 month

0%

YTD

-14.29%

1 year

-47.83%

All time high

0.59

Key Fundamentals

EPS 3 yr Growth

-45.80%

EBITDA Margin

N/A

Operating Cashflow

-$2m

Free Cash Flow Return

-45.00%

ROIC

-61.80%

Interest Coverage

N/A

Quick Ratio

17.90

Other Data

Shares on Issue (Fully Dilluted)

1687m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

1AI Announcements

Latest Announcements

Date Announcements

08 May 25

Peter Mac Partners with Algorae on AI Drug Targets

×

Peter Mac Partners with Algorae on AI Drug Targets

29 April 25

Quarterly Activities Report /Appendix 4C Cash Flow Statement

×

Quarterly Activities Report /Appendix 4C Cash Flow Statement

03 April 25

Algorae Appoints Chief Commercial Officer, Mr Vishal Shah

×

Algorae Appoints Chief Commercial Officer, Mr Vishal Shah

31 March 25

Algorae Receives A$451,359 R&D Cash Rebate from ATO

×

Algorae Receives A$451,359 R&D Cash Rebate from ATO

07 March 25

Cleansing Notice

×

Cleansing Notice

07 March 25

Application for quotation of securities - 1AI

×

Application for quotation of securities - 1AI

26 February 25

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

26 February 25

Half Yearly Report Announcement and Appendix 4D

×

Half Yearly Report Announcement and Appendix 4D

29 January 25

Quarterly Activities Report /Appendix 4C Cash Flow Statement

×

Quarterly Activities Report /Appendix 4C Cash Flow Statement

29 November 24

Significant Cardioprotection Qualities in AI-168 Studies

×

Significant Cardioprotection Qualities in AI-168 Studies

28 November 24

Appointment of Pharmaceutical Executive

×

Appointment of Pharmaceutical Executive

21 November 24

24 New AI-Generated Drug Targets

×

24 New AI-Generated Drug Targets

18 November 24

Proposed issue of securities - 1AI

×

Proposed issue of securities - 1AI

18 November 24

Algorae Discontinues Legacy OTCQB AD Share Program

×

Algorae Discontinues Legacy OTCQB AD Share Program

28 October 24

Appendix 3Y x2

×

Appendix 3Y x2

28 October 24

Notification regarding unquoted securities - 1AI

×

Notification regarding unquoted securities - 1AI

25 October 24

Proposed issue of securities - 1AI

×

Proposed issue of securities - 1AI

25 October 24

Results of Meeting

×

Results of Meeting

25 October 24

AGM Chairman Address to Shareholders

×

AGM Chairman Address to Shareholders

23 October 24

Quarterly Activities Report /Appendix 4C Cash Flow Statement

×

Quarterly Activities Report /Appendix 4C Cash Flow Statement

24 September 24

AlgoraeOS Artificial Intelligence Platform Launched

×

AlgoraeOS Artificial Intelligence Platform Launched

23 September 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

06 September 24

Date of AGM and Closing Date for Director Nominations

×

Date of AGM and Closing Date for Director Nominations

02 September 24

Notification of cessation of securities - 1AI

×

Notification of cessation of securities - 1AI

30 August 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

1AI Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.3 27.3 18.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 40.5 13.0 42.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -29.2 -9.8 -9.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.3 -22.2 -25.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 887 1,347 1,663 Lock Lock Lock
Basic m Lock Lock Lock Lock 887 1,347 1,663 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 98.5 25.0 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.5 10.4 -3.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4.3 10.4 -3.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.0 -7.7 0.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 5 2 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.0 2.9 23.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 4 4 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 4 4 3 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -4 -4 -3 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Equity $m Lock Lock Lock Lock 4 4 3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 4 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 193.0 -6.8 -19.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.8 -50.0 -65.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -48.5 -56.0 -69.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -87.8 -54.6 -65.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -72.3 -54.1 -61.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -75.5 -51.0 -45.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.8 1.9 1.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -105.1 -109.3 -103.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.8 9.4 17.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.8 9.4 17.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 99.3 97.7 97.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -853.6 -441.5 -853.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.8 -50.0 -65.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -48.5 -56.0 -69.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -48.5 -56.0 -69.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 22,121.2 76,041.7 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -22,121.2 -76,041.7 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

1AI Shortsell

Frequently Asked Questions

The current share price of Algorae Pharmaceuticals Limited (1AI:ASX) is AU$0.006.
The 52-week high share price for Algorae Pharmaceuticals Limited (1AI:ASX) is AU$0.01.
The 52-week low share price for Algorae Pharmaceuticals Limited (1AI:ASX)? is AU$0.00.
Algorae Pharmaceuticals Limited (1AI:ASX) does not pay a dividend.
Algorae Pharmaceuticals Limited (1AI:ASX) does not pay a dividend.
Algorae Pharmaceuticals Limited (1AI:ASX) has a franking level of 0.0%.
Algorae Pharmaceuticals Limited (1AI:ASX) is classified in the Healthcare.
The current P/E ratio for Algorae Pharmaceuticals Limited (1AI:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.